Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Controversy about pharmacological modulation of Nrf2 for cancer therapy (CROSBI ID 239959)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Milković, Lidija ; Žarković, Neven ; Saso, Luciano. Controversy about pharmacological modulation of Nrf2 for cancer therapy // Redox Biology, 12 (2017), 727-732. doi: 10.1016/j.redox.2017.04.013

Podaci o odgovornosti

Milković, Lidija ; Žarković, Neven ; Saso, Luciano.

engleski

Controversy about pharmacological modulation of Nrf2 for cancer therapy

Conventional anticancer therapies such as radiotherapy and chemotherapies are associated with oxidative stress generating reactive oxygen species (ROS) and reactive aldehydes like 4-hydroxynonenal in cancer cells that govern them to die. The main mechanism activated due to exposure of the cell to these reactive species is the Nrf2-Keap1 pathway. Although Nrf2 was firstly perceived as a tumor suppressor that inhibits tumor initiation and cancer metastasis, more recent data reveal its role also as a pro-oncogenic factor. Discovery of the upregulation of Nrf2 in different types of cancer supports such undesirable pathophysiological roles of Nrf2. The upregulation of Nrf2 leads to activation of cytoprotective genes thus helping malignant cells to withstand high levels of ROS and to avoid apoptosis, eventually becoming resistant to conventional anticancer therapy. Therefore, new treatment strategies are needed for eradication of cancer and in this review, we will explore two opposing approaches for modulation of Nrf2 in cancer treatments.

Cancer ; Nrf2 ; Oxidative stress ; Cancer therapy ; Growth regulation ; 4-hydroxynonenal

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

12

2017.

727-732

objavljeno

2213-2317

10.1016/j.redox.2017.04.013

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost